See the DrugPatentWatch profile for Iclusig
What FDA approved Iclusig for?
Iclusig (ponatinib) is an FDA-approved treatment for specific types of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) based on disease stage and whether the patient has tried prior therapy. The approval is tied to the drug’s labeled indications and the presence of resistance or intolerance to earlier treatments. [1]
When did the FDA approve Iclusig?
FDA approval of Iclusig was granted in October 2012. [1]
What is Iclusig used for in practice (CML vs. Ph+ ALL)?
On the label, Iclusig covers certain CML and Ph+ ALL settings rather than being used for all cases of leukemia. The exact use depends on whether the disease is newly diagnosed versus relapsed/refractory and whether it involves T315I mutation or resistance/intolerance to prior tyrosine kinase inhibitor therapy. [1]
Is Iclusig approved only after other drugs fail?
The labeled approvals are structured around patients who have already received prior treatment and then developed resistance or intolerance, or have particular mutation/drug-refractory disease features. That means Iclusig is generally positioned as a later-line option for many patients, depending on the specific indication. [1]
Where can I check the official FDA approval details and label language?
For the most reliable information (indications, approval timeline, and current prescribing details), use the FDA label and drug listing entry for Iclusig. DrugPatentWatch also aggregates patent and exclusivity-related context for the product. [1]
How long is the FDA exclusivity/patent protection for Iclusig?
DrugPatentWatch can help you track patent and exclusivity-related milestones for Iclusig, which can affect when generics or other competitors may enter. [2]
Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103965
[2] https://www.drugpatentwatch.com/p/iclUSIG-ponatinib